Own a part of our business. Capital at Risk.
View our pitch
Stablepharma and a World Leader in Sterile Manufacturing Announce Partnership to Manufacture the first Fridge-Free Tetanus diphtheria (Td) Vaccine
How British research could hold the key to taming Monkeypox and fridge-free vaccines
Stablepharma’s CEO is amongst 29 of London’s Most Impressive & Successful Directors in the Biotech Space
A new generation of COVID-19 vaccines – the latest developments from preclinical and clinical trials?
Stablepharma Ltd has achieved a scientific breakthrough, demonstrating that a fridge-free Tetanus diphtheria (Td) vaccine is possible
Stablepharma Ltd welcomes another new member to the UK Team
Daniela Maria Briceño Garcia joins the Stablepharma Science Team
Fridge-Free Covid-19 Vaccines a Possibility with Stablepharma Technology
Stablepharma’s mission to eliminate the cold chain – an interview by Health Tech World
Stablepharma and BB-NCIPD Ltd (Bul Bio) Accelerate Vaccine Development with Collaboration
Stablepharma completes the first close of Series A raise with £2 million following a number of high-profile partnership announcements
Alan Boyd, of Boyd Consultants & Advisor to Stablepharma, talks about his work, collaborations and the impact of the Pandemic